Immunohistochemical detections of EGFR mutations in NSCLC

摘要: In recent years, it has been well known that non-small cell lung cancer (NSCLC) patients with mutations of epidermal growth factor receptor (EGFR) response better to EGFR-tyrosine kinase inhibitor treatment. Although DNA-based assays (e.g. DNA sequencing) are the most frequently used and a relatively reliable method detect EGFR mutations, they complex, time-consuming expensive for routine use in clinical laboratories, besides require high quality tumor samples. contrast, immunohistochemistry (IHC) methods make up fully above shortcomings can serve as screening tests mutations. However, there many factors influence results IHC methods, such different staining procedures, antigen retrieval solutions sets criteria, etc. Thus detecting have not widely clinic only research stage. This article reviews by researchers further discusses how work best detection